Registration Dossier

Diss Factsheets

Toxicological information

Immunotoxicity

Currently viewing:

Administrative data

Endpoint:
immunotoxicity, other
Remarks:
in-vitro
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference
Reference Type:
publication
Title:
HEMA Enhances IgG1 Production by Human B-cells in vitro.
Author:
Andersson J. ad Dahlgren U.
Year:
2010
Bibliographic source:
J Dent Res 89(12):1461-1464

Materials and methods

Principles of method if other than guideline:
The in vitro production of IgG1, IgM, and IgA in supernatants from purified human CD19+
B-lymphocyte cultures, containing different concentrations of HEMA, was assayed with ELISA.
Proliferation was measured by [methyl-3H] thymidine incorporation.
GLP compliance:
not specified

Test material

Constituent 1
Chemical structure
Reference substance name:
2-hydroxyethyl methacrylate
EC Number:
212-782-2
EC Name:
2-hydroxyethyl methacrylate
Cas Number:
868-77-9
Molecular formula:
C6H10O3
IUPAC Name:
2-hydroxyethyl methacrylate
Test material form:
liquid

Results and discussion

Any other information on results incl. tables

Of the different HEMA concentrations used, the lower concentrations of 15 and 37.5 µmol/L caused a significant increase in IgG1 production, but not in IgM or IgA production, in vitro. The lower HEMA concentrations did not significantly change B-cell proliferation. When B-cells were exposed to 75 μmol/L or 150 μmol/L HEMA, no significant changes in IgG1 were demonstrated. At the highest concentration of 750 μmol/L, HEMA significantly suppressed IgG1 and IgM production, as well as B-cell proliferation, in vitro.


 


 

Applicant's summary and conclusion

Conclusions:
In conclusion, HEMA can, at certain concentrations, selectively enhance human B-lymphocyte IgG1 production.